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Summary We report the immunomodulatory effects of an intravenous treatment with FAab')2 fragments of
the bispecific monoclonal antibody BIS-l during subcutaneous recombinant interleukin 2 (rIL-2) therapy of
renal cell cancer (RCC) patients. BIS-1 is directed against both the CD3 antigen on T cells and the EGP-2
molecule on carcinoma cells and some normal epithelia. The amount of BIS-l F(ab'), bound to peripheral
blood lymphocytes (PBLs) increased dose-dependently. This occupation degree was highest at the end of the
2 h infusion and rapidly decreased subsequently. During the first hour of BIS-1 F(ab')2 infusion the number of
PBLs decreased slowly. This was followed by an increase in serum tumour necrosis factor alpha ([NF-a)
concentrations and a rapid decrease in the numbers of peripheral blood lymphocytes. monocytes and
eosinophils. In our view, the most likely explanation for the observed decrease in occupation degree of BIS-1
F(ab')2 and the rise in TNF-a levels is based on the assumption that BIS-1-carrying T cells leave the
circulation. The CD3 antigens on these extravasated T cells become cross-linked by EGP-2 antigens, inducing
TNF-a secretion. This results in an enhanced decrease in the numbers of PBLs. monocytes and eosinophils.
These preliminary results suggest that BIS-1 F(ab'), treatment during IL-2 therapy may induce local T-cell
activation.
Keywords: immunotherapy. bispecific monoclonal antibodies: Iymphocyte activation: tumour necrosis factor
T cells appear to play a key role in interleukin 2 (IL-2)-
induced remissions of immunogenic cancers (Janssen et al.,
1994a). Therefore, improvements of immunotherapy might
be obtained from enhancing T-cell activation, increasing T-
cell migration to tumour sites. and/or reinforcing tumour-cell
recognition by T cells.
IL-2 therapy induces some T-cell activation (Thompson et
al., 1989; Yoshino et al.. 1991), although this was found to
last for only 1-2 weeks (Janssen et al., 1993). In an attempt
to improve tumour-directed T-cell activation we have added
to a standard subcutaneous, recombinant (s.c.) (r) IL-2 treat-
ment an intravenous (i.v.) administration of bispecific
monoclonal antibody BIS-1. BIS-1 is directed against both
the CD3 antigen on T cells [derived from the monoclonal
antibody (MAb) RIV-9] and the EGP-2 molecule (derived
from the MAb MOC-31; De Leij et al., 1994) on carcinoma
cells. EGP-2 is a 38 kDa membrane protein which is abund-
antly present on a large array of normal and malignant
epithelia. The rationale for combining rIL-2 with BIS-1 is
that, in addition to the stimulation of T cells by rIL-2, BIS-1
might guide specific T-cell recognition of tumour cells by
cross-linking the CD3 antigens to EGP-2.
Previously we published the clinical results of the i.v.
application of BIS-1 F(ab'). in RCC patients undergoing
rIL-2 therapy (Kroesen et al., 1994). In the present report we
describe the properties of the antibody in vivo and the
immunomodulatory effects induced by this antibody. The
present results provide insight into the previously observed
toxicity and immunomodulatory aspects accompanying i.v.
administration of BIS-l F(ab')2. These results support our
postulated theory that BIS-1 F(ab')2 loaded T cells leave the
circulation and become activated at EGP-2-positive sites.
Materials and metbods
Patients
Fourteen patients were entered in this study. Patients
received s.c. rIL-2 therapy as described earlier (Sleijfer et at.,
1992). In short, they received a 5 day cycle of Cetus rIL-2
(EuroCetus, Amsterdam, The Netherlands) every week for 4
consecutive weeks. During the first 5 day cycle, 18 x 0O6 IU
rIL-2 were given once daily. In the following cycles the dose
in the first 2 days was reduced to 9 x 106 units. Patients were
treated with BIS-1 F(ab')2 at doses of tLg kg-' (n = 4), or
3 Lg kg-' (n = 4), or 5 Lg kg- (n = 6), administered as a 2 h
i.v. infusion. Each patient received two courses of BIS-1
during s.c. rIL-2 therapy. The first treatment was on the first
day of the second treatment week of IL-2 therapy, and the
second course was on the first or second day of the third
week of IL-2 therapy (Kroesen et al.. 1994). Since no
differences between first and second courses were observed
concerning toxicity or immunomodulatory effects, the results
of both courses are combined in the present report.
Flow cvtometric analysis ofthe amount ofBIS-J F(ab')2
bound to T cells
EDTA-treated blood collected from the patients was immed-
iately placed on ice and all further experiments were carried
out at 0°C unless otherwise stated. To 100 ,Ll samples of
whole blood 4 IL of saturating BIS-1 F(ab')2 (200 ng) was
added to analyse maximal BIS-l-binding capacity of the T
cells or 4 jil phosphate-buffered saline (PBS) to analyse the
in vivo bound BIS-1, and incubated for 30 min. Subsequently.
samples were washed with 2 ml of ice-cold PBS and cent-
rifuged at 1000 g for 2 min. Pellets were resuspended in 50 jil
of goat-anti-mouse-IgG-biotin [GCM-biotin: Southern Bio-
technology Associates (SBA). Birmingham. AL. USA, human
Ig absorbed, 50 jig ml-', containing 1% human pooled serum
and 0.02% sodium]. Control samples were incubated with
50 gl of goat anti-rabbit-IgG-biotin (GaR-biotin; SBA;
human and mouse Ig absorbed). Samples were washed with
ice-cold PBS and incubated with 10 1l of streptavidin-PE
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(SAPE; Becton Dickinson, Mountain View, CA, USA) for
30 min. Subsequently, red blood cells were lysed and cells
were fixed by resuspending the pellets in 2 ml of FACSlysing
solution (Becton Dickinson) for 10 min at room temperature.
After washing with ice-cold PBS, cells were resuspended in
100 gil of PBS and immediately analysed on an Epics Elite
flow cytometer (Coulter Electronics, Hialeah, FL, USA).
Occupation degree was calculated as follows:
(MFI T= x PBS/GaM-biotin/SAPE) -
(MFI T = x PBS/GaR-biotin/SAPE)
(MFI T= x BIS-1 'GaM-biotinlSAPE) -
(MFI T = x BIS-1,GaR-biotin/SAPE)
In this formula, MFI is the mean fluorescence intensity, PBS,
BIS-1, GaM-biotin, GcxR-biotin and SAPE (streptavidin-PE)
indicated the agents which were added to the samples and
T= x indicates time point of analysis.
Flow cvtometric analysis offree BIS-J F(ab').fragments
To determine the presence of unbound BIS-1 F(ab')2, whole
blood samples of healthy donors were incubated with 20 il
aliquots of plasma taken at T =0 h and T= 2 h. Further
staining procedure to detect cell bound BIS-I was performed
as described above.
days in a carbon dioxide incubator in a humidified atmos-
phere at 3rC. A 25 gl sample (0.5 gLCi) of a [3Hlthymidine
solution (specific activity of 400 mCi mmol ') was added to
the cultures, 16 h before harvesting. Incorporation was
counted in tnrplicate and expressed as disintegrations per
second (DPS).
Leucoci te counting anddifferentiation
Leucocyte numbers and leucocyte differentiations were deter-
mined in EDTA-treated whole blood samples using the
Coulter SKS.
Results
Amount ofcell bound BIS-J (Fab')} decreases in time
The amount of BIS-1 F(ab'), bound to the cell surface of
blood lymphocytes was expressed as the occupation degree of
BIS-I F(ab'), (see Materials and methods). The occupation
100
In vitro modulation ofBIS-J Flab').
Whole blood samples of healthy donors were incubated with
various concentrations of BIS-l F(ab'). for 30 min at 0°C. In
one-half of the samples, unbound antibodies were washed
away. whereas the other half was left untreated. Subse-
quently, the samples were incubated for various times at 0°C
or 37C. Staining of the samples to detect cell bound BIS-I
was performed as described above. The amount of modula-
tion was determined by dividing the MFI at 37C by the
MFI at 0°C.
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TNFa concentrations in plasma were determined using a
commercially available ELISA (Eurogenetics, Belgium). ED-
TA-treated blood was immediately put on ice after collection
and plasma was obtained after centrifugation at 4°C and
stored at -20'C until analysis.
Lymphocyteproliferation
Lymphocyte proliferation assays were performed as described
earlier (Janssen et al., 1994b). Heparinised human peripheral
blood from IL-2-treated patients was diluted 1:9 with RPMI-
1640 medium supplemented with 2% heat-inactivated human
pooled serum. BIS-l F(ab')2 or BIS-1 IgG was added at a
concentration of 0.1 ig ml-'. Irradiated (4800 rad) EGP-2-
positive (GLC-lM13) or EGP-2-negative (GLC-1) target cells
were added at a concentration of 2 x I0 cells ml'- . Aliquots
of 100gil of these cell mixtures were added in triplicate to
round-bottom wells of a 96-well plate and incubated for 3
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Figwe 1 Modulation of BIS-1 F(ab')2 in vitro. Whole blood
samples of healthy donors were incubated with various concent-
rations of BIS-1 F(ab') at O-C for 30 min. Subsequently samples
were washed (-0 ) or not ( ) and incubated at
3TC or O-C. Samples were stained as stated in the Materials and
methods section. Values are expressed as mean fluorescence inten-
sity (MFI) of samples incubated at 3TC divided by the MFI of
samples incubated at O-C. Results are from one representative
experiment out of three.
Table 1 Occupation degrees ofCD3 antigens by BIS-1 F(ab) in Vivo and after in vitro incubation of
cells taken at T= 2 h
In vivoa In vitrob
Dose'c nd T=2h T=3h T=5h T=2h+1h T=2h+3h
1 4 1.0 0.4 0.4±0.4 0.1±0.1 ND ND
3 8 4.2±1.0 2.1±0.6 0.9±0.5 ND ND
Patient 8' 6.2 1.8 0.7 3.6 2.9
5 9 5.6 ± 3.2 2.7 ± 0.9 1.8 ± 0.8 7.1 ± 4.5 4.5 ± 2.2
aMean values ofoccupation degrees ± s.d. ofsamples taken at T= 2 h, T = 3 hand T = 5 h. bMean
values ofoccupation degrees ± s.d. ofsamples taken at T = 2 h and incubated for I h (T= 2 h + 1 h)
and 3 h (T= 2 h + 3 h) at 3TC. CDose ofBIS-1 F(ab}) administered(gigkg-' body weight).dNumber
ofcourses in which occupation degreesweredetermined. 'Values forpatient 8 treated atday 23 ofIL-2
therapy with 3gg kg-' BIS-1 F(ab%k. Sinceonlythelymphocytesofpatient8areusedasanexample of
the 3 jig kg- dose forin vitrostudiesall valuesobtainedwith thispatientaregivenseparately. ND,not
determined.degree of BIS-1 F(ab')2 immediately at the end of the 2 h
infusion (T= 2 h) increased dose dependently (Table I, col-
umn 3). Subsequent analysis at various time points after
ending the infusion, showed that the occupation degree of
BIS-1 F(ab'), decreased quickly in time at all treatment
concentrations (Table I, in vivo data).
To study the possibility that the i.v. BIS-1 F(ab')2 treat-
ment had induced down-modulation of CD3 antigens itself
on peripheral blood T cells, the MFI of the various samples
taken in time incubated with saturating BIS-1 F(ab')2 at 0'C
(to prevent modulation during staining) for 30 min was
measured. MFl values of samples taken at T= 2 h, T= 3 h
and T = 5 h were comparable to pretreatment values (not
shown), indicating that no significant modulation of the CD3
antigen itself had occurred in vivo.
Immediately after ending the infusion (T = 2 h), non-cell-
bound BIS-1 F(ab')2 fragments were present in plasma of
patients treated with 3 or 5 gg kg- (plasma samples of
patients treated with 1 gig kg-' were not analysed). Whole
blood samples of healthy donors were stained with plasma of
the patients (see Materials and methods). In all cases an
a
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increase in MFl from T= 0 h to T= 2 h. varying from 2 to
16%. was observed.
In vitro modulation of BIS-1 F(ab')2
The decrease in time of BIS-1 F(ab')2 occupation in vivio
could be due to the fact that only CD3 molecules with bound
BIS-1 F(ab')2 become modulated. We have studied such a
possibility by performing in vitro experiments.
Firstly, whole blood samples from BIS-1 F(ab')2-treated
patients (3 or 5ptgkg-') taken at T=2h (end of infusion)
were further incubated in vitro at 3TC for 1 and 3 h, before
staining and fixing, mimicking the in i'ivo situation. In
patients treated with 5 jig kg-' the occupation degree in-
creased during the first hour of in vitro incubation
(T= 2 h + I h) after which the occupation degree decreased
again (T = 2 h + 3 h). However, this decrease was not as
pronounced as in vivo (Table I, in vitro data). The same
experiment was performed with whole blood samples taken
from patient 8 (3 i'g kg-'). In this case, the occupation
b
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Figure 2 Changes in leucocyte numbers in three patients before (T= Oh), during (T = 0.5 h. I h, 1.5 h, 2 h), and after treatment
(T = 3 h, 5 h) with 5 jug kg-' body weight. The results of each treatment are shown, (total of five treatments, except in d where only
four treatments are shown). (a) Changes in lymphocytes. (b) Changes in monocytes. (c) Changes in neutrophils. (d) Changes in
eosinophils.
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degree during in vitro incubation decreased continuously, but
not as much as the in vivo decrease.
Secondly. to study BIS-1 F(ab')2 modulation in more
detail, the effect of vanrous concentrations of BIS-1 F(ab')2
on whole blood samples of healthy donors was tested. Figure
1 shows that there is only moderate modulation (<20%) at
low concentrations (<100 ng ml') of antibody, whereas
high concentrations (>100 ng ml-') induced modulation up
to 80%. Modulation was higher when the antibody was not
washed away.
BIS-J F(ab'}. treatment induces lymphopenia
BIS-1 F(ab')2 administration at 3 and Sligkg-', but not at
1 ;Lg kg-'. induced leucopenia. Leucopemia was moderate at
3tig kg-' but profound effects were seen at 5 Lg kg-'. After
24 h. leucocyte numbers had almost, but not completely.,
returned to their pretherapy values (not shown). Changes in
leucocyte numbers during the 2 h infusion are given in detail
in Figure 2. In patients treated with 5 ytg kg-' BIS-l F(ab')2,
the number of lymphocytes decreased slowly but immediately
from T= Oh to T= 1.5 h, followed by a more rapid decrease
until T= 3 h. The number of monocytes stayed stable or
increased during the first hour followed by a rapid dis-
appearance of virtually all monocytes within the following
hour. The number of eosinophils followed a pattern com-
parable to that of the lymphocytes. In contrast to the strong
decrease of these cell types, the number of neutrophils
decreased only moderately during the last half hour of
infusion, after which the amount increased again, exceeding
preinfusion levels.
BIS-I FRab'v treatment induces T.VF-a production
Levels of plasma TNF-a were determined in two patients
before and during the infusion of 5 tg kg-' BIS-l F(ab')2 at
half hour time intervals. Figure 3 shows that BIS-1 F(ab')2
treatment induced an increase in TNF-a levels between
T= I h and T= 1.5 h. TNF-a reached peak levels at T= 2 h
after which the levels of TNF-x decreased rapidly again (as
demonstrated in one patient).
BIS-J F(ab') treatment induces lymphocyte proliferation only
in the presence ofEGP-2
To study the specificity of BIS-1 F(ab')2 and how BIS-1
F(ab')2 may affect lymphocyte activation during IL-2 ther-
apy, whole blood samples taken from RCC patients receiving
IL-2 therapy were incubated with BIS-1 F(ab')2 in the
presence of EGP-2-positive or EGP-2-negative tumour cells.
Figure 4 shows that BIS-1 F(ab') induces lymphocyte pro-
liferation only in the presence of EGP-2-positive tumour
cells. Using BIS-1 IgG instead of BIS-1 F(ab')2 resulted in
higher proliferation rates in all cases.
Discussion
This study describes the properties of intravenously admin-
istered BIS-1 in terms of its binding capacity to lymphocytes
and of its effects on leucocyte and lymphocyte subpopula-
tions. In an earlier study we found the unexpected result that
BIS-1 treatment of RCC patients induces lymphopenia and
TNF-x production (Kroesen et al.. 1994). The present study
of the behaviour of the BIS-1 F(ab')2 antibody and the more
detailed study of the immunomodulatory effects dunrng
infusion of the antibody may explain this surprising pheno-
menon, as will be discussed here.
After ending the i.v. infusion of BIS-1 F(ab')2 the amount
of cell bound to BIS-1 F(ab')2 appears to decrease quickly in
time. There are two conceivable explanations for this
phenomenon. Firstly, CD3 molecules which have bound BIS-1
F(ab') could become internalised. Secondly, T cells which
have bound BIS-1 F(ab')2 leave the circulation causing a
decrease in the observed MFI of BIS-1 F(ab')2 expression
on T cells. Both possibilities will be discussed here.
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Figure 4 Proliferation of PBLs of IL-2 patients induced by
BIS-1. Whole blood samples were taken from IL-2 patients at
different time points during IL-2 therapy. Ten times diluted
samples were incubated with EGP-2-positive (GLC-lM13) targets
( - ), EGP-2 negative (GLC-1) targets ( ), or no targets
(LIII) in the presence of BIS-1 F(ab). Proliferation was
measured as disintegrations per second (DPS).
It has been reported that in vitro CD3 MAbs become
down modulated from the T-cell surface due to internal-
isation of the CD3 molecule/CD3 MAb complex (Boyer et
al.. 1991). The rate and degree of internalisation of
monovalent Fab-fragments of OKT3 in those studies
appeared to be lower than those of intact Ig. Figure 1
shows that BIS-1 F(ab'), fragments, containing one Ag
binding site of the CD3 MAb RIV-9, also induce modula-
tion in vitro, at least at high concentrations. The modul-
ation of BIS-1 F(ab')2 was higher when free antibodies were
not washed away after in vitro incubation of cells with
BIS-l F(ab')2 (Figure 1). This resembles earlier findings
with whole Ig CD3 MAb (van Oosterhout et al., 1992). The
presence of free antibodies will shift the equilibrium from
free antigens towards MAb bound antigens resulting in
enhanced internalisation rates.
Instead of modulation, dissociation of BIS-1 F(ab')2 from
its antigen during falling antibody concentrations may
occur. However, washing away of the antibody before fur-
ther incubation at O'C (mimicking falling antibody concent-
rations in vivo) did not result in a lower MFI signal com-
pared to the situation in which the antibody was not
washed away (not shown), suggesting that decrease in sol-
uble antibody concentrations does not induce dissociation.
L--L a . a - . M---I-Imnomoduatoy effed s of bis4ecfk MAb in vwv
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Although modulation and or dissociation of BIS-1 F-
(ab')2 might partly be responsible for the decrease of BIS-1
F(ab')2 on the T-cell surface, several considerations argue
against this as the main mechanism. Firstly, mimicking the
in vivo situation by in vitro incubation at 37°C of blood
samples taken immediately after infusion, did not induce a
decrease but, in contrast, induced an increase in cell-bound
BIS-1 F(ab')2 at 5 tg kg-' during the first hour (T= 2
h + 1 h) of incubation (Table I, in vitro data). The subse-
quent decrease in bound BIS-1 (T= 2 h + 3 h) in vitro
(Table I), however, might still be due to some modulation.
The increase in cell bound BIS-1 F(ab')2 during the first
hour of incubation suggests that at this dose and at
T= 2 h, free BIS-l F(ab')2 fragments are still present in the
circulation, which may bind to the cells during extended in
vitro incubation. Indeed, the positive staining of whole
blood samples of healthy donors with plasma isolated at
this time point from these BIS-1-treated patients indicates
that there are free BIS-1 F(ab')2 fragments. The increased
binding of BIS-1 F(ab')2 fragments in vitro (which appar-
ently does not occur in vivo) may reach a certain level of
saturation which induces subsequently the observed modul-
ation in vitro.
A second argument against modulation is that the con-
centrations of BIS-1 F(ab')2 in the circulation (maximum
14. 42. and 70ngml-' at 1. 3 and 5Agkg-1 respectively
assuming an equal distribution over 5 1 of blood) are prob-
ably not high enough to induce modulation, since the in vitro
studies show that only concentrations higher than 100
ngm1-1 induce significant modulation (Figure 1).
Thirdly, the MFI of CD3-immunostained T cells,
reflecting the total number of CD3 antigens present on the
T-cell surface, did not change during treatment. These
results suggest that the decrease in bound BIS-1 is not due
to modulation only. Another possible explanation for the
decreased detection of bound BIS-1 is that BIS-1 occupied
T cells leave the peripheral blood compartment resulting in
the virtual decrease in PBL-bound BIS-1. This is supported
by the observed transitory reduction in leucocyte counts
during and after the BIS-1 infusion.
The production of TNF-a is rather surprising, since
TNF-a production by T cells is only induced by cross-
linking of CD3 antigens (Woodle et al.. 1991). In this study
we used F(ab')2 fragments of a bispecific MAb. implying
that no cross-linking of CD3 Ag can be induced by this
MAb. The absence of an Fc portion also excludes the
possibility of TNFzx production by monocytes. In addition.
the BIS-1 F(ab')2 preparation is endotoxin-free. Tibben et
al. (1993) showed that i.v. administration of F(ab')2
fragments of a bispecific MAb against CD3 (OKT3-derived)
and an ovarian carcinoma associated antigen (recognised by
the MAb MOv18) also induced high levels of serum TNF-m.
This last trial was performed without concomitant IL-2
therapy. So. it is unlikely that the concomitant IL-2 therapy
in the present study is responsible for the induction of
TNF-m.
The results of the proliferation assays shown in Figure 4
demonstrate that lymphocytes are activated only when
EGP-2 positive cells are present. A conceivable explanation
for the increase in TNF-( levels. thus. is local production of
TNF-m by T cells following cross-linking of CD3 antigens
with EGP-2 antigens. The latter are only present on tumour
cells or on normal epithelia, and therefore TNF-a secretion
can only occur after T-cell extravasation. This idea is sup-
ported by the slow but immediate decrease in lymphocyte
numbers after starting the infusion (Figure 2a). without a
concomitant rise in serum TNF-m dunrng the first hour of
infusion. The subsequent local start of production of TNF-m
might lead then to extravasation of various leucocytes in-
cluding lymphocytes. monocytes and eosinophils of which
monocytes form the fastest responding population. The
numbers of neutrophils decreased only moderately and was
only temporary. We currently do not know why neutrophils
behave differently. but one conceivable explanation may be
the lack of VLA-4 expression on neutrophils. in contrast to
lymphocytes. monocytes and eosinophils which are VLA-4-
positive. VLA-4 VCAM-1 interactions play an important
role in leucocyte extravasation.
In summary. these results form the first evidence that
BIS-1 F(ab').-loaded T cells leave the circulation and
become locally activated by cross-linking of their CD3
antigens via EGP-2. This results in a local but subsequently
also systemic inflammatory reaction. which might be suppor-
tive for immune cell-mediated tumour regression.
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